Cargando…
The PIM family of oncoproteins: Small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets
PIM kinases are a family of serine/threonine kinases involved in cell survival and proliferation. There is significant structural similarity between the three PIM kinases (PIM1, PIM2 and PIM3) and few amino acid differences. Although, several studies have specifically monitored the role of PIM1 in t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226700/ https://www.ncbi.nlm.nih.gov/pubmed/25238262 |
_version_ | 1782343663758606336 |
---|---|
author | Saurabh, Kumar Scherzer, Michael T. Shah, Parag P. Mims, Alice S. Lockwood, William W. Kraft, Andrew S. Beverly, Levi J. |
author_facet | Saurabh, Kumar Scherzer, Michael T. Shah, Parag P. Mims, Alice S. Lockwood, William W. Kraft, Andrew S. Beverly, Levi J. |
author_sort | Saurabh, Kumar |
collection | PubMed |
description | PIM kinases are a family of serine/threonine kinases involved in cell survival and proliferation. There is significant structural similarity between the three PIM kinases (PIM1, PIM2 and PIM3) and few amino acid differences. Although, several studies have specifically monitored the role of PIM1 in tumorigenesis, much less is known about PIM2 and PIM3. Therefore, in this study we have used in vitro cell culture models and in vivo bone marrow infection/transplantation to assess the comparative signaling and oncogenic potential of each of the three PIM kinases. All three PIM kinases were able to protect FL5.12 cells from IL-3 withdrawal induced death. Interestingly, the downstream signaling cascades were indistinguishable between the three kinases. Transplantation of murine bone marrow co-expressing MYC and PIM1, PIM2 or PIM3 caused rapid and uniformly lethal myeloid leukemia. De-induction of MYC 18 days following transplantation significantly increased the survival of mice, even with continual expression of PIM kinases. Alternatively, mice treated at the pre-leukemic stage with a PIM kinase inhibitor increased the lifespan of the mice, even with continual expression of the MYC transgene. These data demonstrate the role of PIM kinases in driving myeloid leukemia, and as candidate molecules for therapy against human malignancies. |
format | Online Article Text |
id | pubmed-4226700 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-42267002014-11-17 The PIM family of oncoproteins: Small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets Saurabh, Kumar Scherzer, Michael T. Shah, Parag P. Mims, Alice S. Lockwood, William W. Kraft, Andrew S. Beverly, Levi J. Oncotarget Research Paper PIM kinases are a family of serine/threonine kinases involved in cell survival and proliferation. There is significant structural similarity between the three PIM kinases (PIM1, PIM2 and PIM3) and few amino acid differences. Although, several studies have specifically monitored the role of PIM1 in tumorigenesis, much less is known about PIM2 and PIM3. Therefore, in this study we have used in vitro cell culture models and in vivo bone marrow infection/transplantation to assess the comparative signaling and oncogenic potential of each of the three PIM kinases. All three PIM kinases were able to protect FL5.12 cells from IL-3 withdrawal induced death. Interestingly, the downstream signaling cascades were indistinguishable between the three kinases. Transplantation of murine bone marrow co-expressing MYC and PIM1, PIM2 or PIM3 caused rapid and uniformly lethal myeloid leukemia. De-induction of MYC 18 days following transplantation significantly increased the survival of mice, even with continual expression of PIM kinases. Alternatively, mice treated at the pre-leukemic stage with a PIM kinase inhibitor increased the lifespan of the mice, even with continual expression of the MYC transgene. These data demonstrate the role of PIM kinases in driving myeloid leukemia, and as candidate molecules for therapy against human malignancies. Impact Journals LLC 2014-08-13 /pmc/articles/PMC4226700/ /pubmed/25238262 Text en Copyright: © 2014 Saurabh et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Saurabh, Kumar Scherzer, Michael T. Shah, Parag P. Mims, Alice S. Lockwood, William W. Kraft, Andrew S. Beverly, Levi J. The PIM family of oncoproteins: Small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets |
title | The PIM family of oncoproteins: Small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets |
title_full | The PIM family of oncoproteins: Small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets |
title_fullStr | The PIM family of oncoproteins: Small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets |
title_full_unstemmed | The PIM family of oncoproteins: Small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets |
title_short | The PIM family of oncoproteins: Small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets |
title_sort | pim family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226700/ https://www.ncbi.nlm.nih.gov/pubmed/25238262 |
work_keys_str_mv | AT saurabhkumar thepimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets AT scherzermichaelt thepimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets AT shahparagp thepimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets AT mimsalices thepimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets AT lockwoodwilliamw thepimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets AT kraftandrews thepimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets AT beverlylevij thepimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets AT saurabhkumar pimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets AT scherzermichaelt pimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets AT shahparagp pimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets AT mimsalices pimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets AT lockwoodwilliamw pimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets AT kraftandrews pimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets AT beverlylevij pimfamilyofoncoproteinssmallkinaseswithhugeimplicationsinmyeloidleukemogenesisandastherapeutictargets |